CA2999332A1 - Forme cristalline de 2- (2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl -3,4-dihydroisoquinolein -2 (1h)-yl)ethanone pour le traitement de la maladie de parkinson - Google Patents

Forme cristalline de 2- (2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl -3,4-dihydroisoquinolein -2 (1h)-yl)ethanone pour le traitement de la maladie de parkinson Download PDF

Info

Publication number: CA2999332A1
Authority: CA; Canada
Prior art keywords: methyl; compound; mmol; dihydroisoquinolin; hydroxy
Prior art date: 2015-10-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2999332A

Other languages

English (en)

Inventor

Gregory Alan Stephenson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-23

Filing date

2016-10-18

Publication date

2017-04-27

2016-10-18 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2017-04-27 Publication of CA2999332A1 publication Critical patent/CA2999332A1/fr

Status Abandoned legal-status Critical Current

Links

208000018737 Parkinson disease Diseases 0.000 title claims abstract description 23
XHCSBQBBGNQINS-DOTOQJQBSA-N 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone Chemical compound N1([C@H](C2=CC=CC(CCC(C)(C)O)=C2C[C@@H]1CO)C)C(=O)CC1=C(Cl)C=CC=C1Cl XHCSBQBBGNQINS-DOTOQJQBSA-N 0.000 title claims abstract 5
238000011282 treatment Methods 0.000 title claims description 15
238000000034 method Methods 0.000 claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
150000001875 compounds Chemical class 0.000 claims description 103
238000000634 powder X-ray diffraction Methods 0.000 claims description 7
230000005855 radiation Effects 0.000 claims description 5
238000002560 therapeutic procedure Methods 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
208000010877 cognitive disease Diseases 0.000 abstract description 5
201000000980 schizophrenia Diseases 0.000 abstract description 4
208000028698 Cognitive impairment Diseases 0.000 abstract description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 97
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 40
239000000203 mixture Substances 0.000 description 37
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
238000003756 stirring Methods 0.000 description 36
239000012141 concentrate Substances 0.000 description 32
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 30
230000015572 biosynthetic process Effects 0.000 description 27
238000003786 synthesis reaction Methods 0.000 description 27
VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 25
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
239000007787 solid Substances 0.000 description 24
239000000243 solution Substances 0.000 description 24
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 23
238000002360 preparation method Methods 0.000 description 23
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
239000000284 extract Substances 0.000 description 20
102000005962 receptors Human genes 0.000 description 18
108020003175 receptors Proteins 0.000 description 18
229940125904 compound 1 Drugs 0.000 description 17
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
239000013078 crystal Substances 0.000 description 15
229960003638 dopamine Drugs 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 13
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 13
230000006742 locomotor activity Effects 0.000 description 13
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 13
229960003147 reserpine Drugs 0.000 description 13
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 13
238000010898 silica gel chromatography Methods 0.000 description 13
229910052938 sodium sulfate Inorganic materials 0.000 description 13
235000011152 sodium sulphate Nutrition 0.000 description 13
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 12
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
241000699670 Mus sp. Species 0.000 description 12
239000002904 solvent Substances 0.000 description 11
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
239000003921 oil Substances 0.000 description 9
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
239000012267 brine Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
239000003054 catalyst Substances 0.000 description 7
239000010410 layer Substances 0.000 description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
239000002002 slurry Substances 0.000 description 7
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
229910016523 CuKa Inorganic materials 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
238000003556 assay Methods 0.000 description 6
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000003446 ligand Substances 0.000 description 6
230000008569 process Effects 0.000 description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
230000003281 allosteric effect Effects 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
230000033001 locomotion Effects 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
QNSTWZBFWXFFJP-SBSPUUFOSA-N (3R)-5-bromo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride Chemical compound Cl.OC(=O)[C@H]1Cc2c(Br)cccc2CN1 QNSTWZBFWXFFJP-SBSPUUFOSA-N 0.000 description 4
SFAILOOQFZNOAU-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=C(Cl)C=CC=C1Cl SFAILOOQFZNOAU-UHFFFAOYSA-N 0.000 description 4
HNVRRHSXBLFLIG-UHFFFAOYSA-N 3-hydroxy-3-methylbut-1-ene Chemical compound CC(C)(O)C=C HNVRRHSXBLFLIG-UHFFFAOYSA-N 0.000 description 4
206010001541 Akinesia Diseases 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
235000019270 ammonium chloride Nutrition 0.000 description 4
229940125782 compound 2 Drugs 0.000 description 4
239000012043 crude product Substances 0.000 description 4
239000002027 dichloromethane extract Substances 0.000 description 4
238000002050 diffraction method Methods 0.000 description 4
IAVCINLGBBDZKM-LLVKDONJSA-N dimethyl (3R)-5-bromo-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylate Chemical compound COC(=O)[C@H]1Cc2c(Br)cccc2CN1C(=O)OC IAVCINLGBBDZKM-LLVKDONJSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000002024 ethyl acetate extract Substances 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
238000001543 one-way ANOVA Methods 0.000 description 4
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 4
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
-1 tetrafluoroborate Chemical compound 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
206010052804 Drug tolerance Diseases 0.000 description 3
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 3
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
238000002441 X-ray diffraction Methods 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
239000012346 acetyl chloride Substances 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
235000011089 carbon dioxide Nutrition 0.000 description 3
238000002288 cocrystallisation Methods 0.000 description 3
239000012230 colorless oil Substances 0.000 description 3
238000000113 differential scanning calorimetry Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000003550 marker Substances 0.000 description 3
RONHJWCWYGBEPT-SBSPUUFOSA-N methyl (2R)-2-amino-3-(2-bromophenyl)propanoate hydrochloride Chemical compound Cl.COC(=O)[C@H](N)Cc1ccccc1Br RONHJWCWYGBEPT-SBSPUUFOSA-N 0.000 description 3
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
229940126027 positive allosteric modulator Drugs 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000010791 quenching Methods 0.000 description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
JFVLNTLXEZDFHW-MRVPVSSYSA-N (2r)-2-azaniumyl-3-(2-bromophenyl)propanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CC1=CC=CC=C1Br JFVLNTLXEZDFHW-MRVPVSSYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
IJLORLGDTCOFRU-HNCPQSOCSA-N Cl.COC(=O)[C@H]1Cc2c(Br)cccc2CN1 Chemical compound Cl.COC(=O)[C@H]1Cc2c(Br)cccc2CN1 IJLORLGDTCOFRU-HNCPQSOCSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
239000005909 Kieselgur Substances 0.000 description 2
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241001085205 Prenanthella exigua Species 0.000 description 2
RFDUOEZRCGXWBG-CYBMUJFWSA-N [(3R)-5-bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC[C@H]1Cc2c(Br)cccc2CN1 RFDUOEZRCGXWBG-CYBMUJFWSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000005587 bubbling Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
HOXDXGRSZJEEKN-UHFFFAOYSA-N cycloocta-1,5-diene;rhodium Chemical compound [Rh].C1CC=CCCC=C1 HOXDXGRSZJEEKN-UHFFFAOYSA-N 0.000 description 2
IDLVJIDYJDJHOI-UHFFFAOYSA-N cyclopenta-2,4-dien-1-yl-di(propan-2-yl)phosphane;iron(2+) Chemical compound [Fe+2].CC(C)P(C(C)C)C1=CC=C[CH-]1.CC(C)P(C(C)C)C1=CC=C[CH-]1 IDLVJIDYJDJHOI-UHFFFAOYSA-N 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
229940052760 dopamine agonists Drugs 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
BAQKJENAVQLANS-UHFFFAOYSA-N fenbutrazate Chemical compound C=1C=CC=CC=1C(CC)C(=O)OCCN(C1C)CCOC1C1=CC=CC=C1 BAQKJENAVQLANS-UHFFFAOYSA-N 0.000 description 2
229960002533 fenbutrazate Drugs 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000026781 habituation Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
229940011051 isopropyl acetate Drugs 0.000 description 2
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
229960004502 levodopa Drugs 0.000 description 2
230000003137 locomotive effect Effects 0.000 description 2
CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
239000010445 mica Substances 0.000 description 2
229910052618 mica group Inorganic materials 0.000 description 2
208000027061 mild cognitive impairment Diseases 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
238000013105 post hoc analysis Methods 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
229960003089 pramipexole Drugs 0.000 description 2
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000010926 purge Methods 0.000 description 2
239000012925 reference material Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
HLFFVUHRTCBSJR-LLVKDONJSA-N tert-butyl (3R)-5-bromo-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate Chemical compound CC(C)(C)OC(=O)N1Cc2cccc(Br)c2C[C@@H]1CO HLFFVUHRTCBSJR-LLVKDONJSA-N 0.000 description 2
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
229910052723 transition metal Inorganic materials 0.000 description 2
150000003624 transition metals Chemical class 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
238000011870 unpaired t-test Methods 0.000 description 2
238000003828 vacuum filtration Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
YUHZIUAREWNXJT-UHFFFAOYSA-N (2-fluoropyridin-3-yl)boronic acid Chemical class OB(O)C1=CC=CN=C1F YUHZIUAREWNXJT-UHFFFAOYSA-N 0.000 description 1
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
238000004791 1D NOESY Methods 0.000 description 1
241000349731 Afzelia bipindensis Species 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006100 Bradykinesia Diseases 0.000 description 1
MKYCSDYXKSXVAW-QWHCGFSZSA-N C[C@@H]1N[C@@H](CO[Si](C)(C)C(C)(C)C)Cc2c(Br)cccc12 Chemical compound C[C@@H]1N[C@@H](CO[Si](C)(C)C(C)(C)C)Cc2c(Br)cccc12 MKYCSDYXKSXVAW-QWHCGFSZSA-N 0.000 description 1
KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
238000001061 Dunnett's test Methods 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
101000958041 Homo sapiens Musculin Proteins 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
239000012448 Lithium borohydride Substances 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241000233805 Phoenix Species 0.000 description 1
206010071390 Resting tremor Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
FWPADHASRYCESP-MRVPVSSYSA-N [(3R)-5-bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol Chemical compound OC[C@H]1Cc2c(Br)cccc2CN1 FWPADHASRYCESP-MRVPVSSYSA-N 0.000 description 1
KVDGQYSNPCEQPH-CYBMUJFWSA-N [(3R)-5-bromo-3,4-dihydroisoquinolin-3-yl]methoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC[C@H]1Cc2c(Br)cccc2C=N1 KVDGQYSNPCEQPH-CYBMUJFWSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
229960004596 cabergoline Drugs 0.000 description 1
244000309466 calf Species 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000007278 cognition impairment Effects 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
210000005064 dopaminergic neuron Anatomy 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical compound CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 description 1
229960001820 etilevodopa Drugs 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000021824 exploration behavior Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
OROHIIJXVPDPBS-UHFFFAOYSA-N fluoro 3,4-difluoroazete-2-carboxylate Chemical compound FOC(=O)C1=NC(F)=C1F OROHIIJXVPDPBS-UHFFFAOYSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
230000036541 health Effects 0.000 description 1
238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
102000046949 human MSC Human genes 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
238000010150 least significant difference test Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960001794 melevodopa Drugs 0.000 description 1
XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
GNVRJGIVDSQCOP-UHFFFAOYSA-N n-ethyl-n-methylethanamine Chemical compound CCN(C)CC GNVRJGIVDSQCOP-UHFFFAOYSA-N 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000012587 nuclear overhauser effect experiment Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229960004851 pergolide Drugs 0.000 description 1
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000001907 polarising light microscopy Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
229960001879 ropinirole Drugs 0.000 description 1
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
229960003179 rotigotine Drugs 0.000 description 1
KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
150000003839 salts Chemical group 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000012453 solvate Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2999332A 2015-10-23 2016-10-18 Forme cristalline de 2- (2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl -3,4-dihydroisoquinolein -2 (1h)-yl)ethanone pour le traitement de la maladie de parkinson Abandoned CA2999332A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562245391P	2015-10-23	2015-10-23
US62/245,391		2015-10-23
PCT/US2016/057447 WO2017070068A1 (fr)	2015-10-23	2016-10-18	Forme cristalline de 2- (2,6-dichlorophényl)-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl -3,4-dihydroisoquinoléin -2 (1h)-yl)éthanone pour le traitement de la maladie de parkinson

Publications (1)

Publication Number	Publication Date
CA2999332A1 true CA2999332A1 (fr)	2017-04-27

Family

ID=57233858

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2999332A Abandoned CA2999332A1 (fr)	2015-10-23	2016-10-18	Forme cristalline de 2- (2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl -3,4-dihydroisoquinolein -2 (1h)-yl)ethanone pour le traitement de la maladie de parkinson

Country Status (13)

Country	Link
CN (1)	CN108137506A (fr)
AR (1)	AR106332A1 (fr)
AU (1)	AU2016341115A1 (fr)
CA (1)	CA2999332A1 (fr)
DO (1)	DOP2018000103A (fr)
EA (1)	EA201890525A1 (fr)
EC (1)	ECSP18030976A (fr)
IL (1)	IL257872A (fr)
MX (1)	MX2018004794A (fr)
PE (1)	PE20181296A1 (fr)
PH (1)	PH12018500859A1 (fr)
TW (1)	TW201725199A (fr)
WO (1)	WO2017070068A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI725408B (zh)	2018-04-20	2021-04-21	美商美國禮來大藥廠	多巴胺d1受體正向異位調節劑
FI3897578T3 (fi)	2018-12-18	2025-01-03	Lilly Co Eli	Annosteluohjelmia ly3154207:n käyttöön dopaminergisten keskushermostohäiriöiden hoidossa
TWI843678B (zh) *	2019-06-18	2024-05-21	美商美國禮來大藥廠	用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
CN117377470A (zh) *	2021-03-08	2024-01-09	伊莱利利公司	美维达林和其他d1正向别构调节剂在幻觉和痴呆相关精神病的治疗中的用途
BR112023018196A2 (pt) *	2021-03-09	2023-12-12	Lilly Co Eli	Uso de mevidalen e outros moduladores alostéricos positivos d1 para retardar a progressão da doença de parkinson
CN113264926A (zh) *	2021-05-31	2021-08-17	东北林业大学	一种牡荆素与利血平的共晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5236934A (en) *	1992-08-26	1993-08-17	E. I. Du Pont De Nemours And Company	1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
RU2009136330A (ru) *	2007-03-01	2011-04-10	Янссен Фармацевтика Н.В. (Be)	Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора
US20120252853A1 (en) *	2011-04-01	2012-10-04	H. Lundbeck A/S	Positive allosteric modulators of nicotinic acetylcholine receptor
JO3316B1 (ar) *	2013-05-30	2019-03-13	Lilly Co Eli	مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

2016
- 2016-10-13 AR ARP160103122A patent/AR106332A1/es unknown
- 2016-10-14 TW TW105133203A patent/TW201725199A/zh unknown
- 2016-10-18 MX MX2018004794A patent/MX2018004794A/es unknown
- 2016-10-18 WO PCT/US2016/057447 patent/WO2017070068A1/fr not_active Ceased
- 2016-10-18 CA CA2999332A patent/CA2999332A1/fr not_active Abandoned
- 2016-10-18 EA EA201890525A patent/EA201890525A1/ru unknown
- 2016-10-18 CN CN201680061907.6A patent/CN108137506A/zh active Pending
- 2016-10-18 AU AU2016341115A patent/AU2016341115A1/en not_active Abandoned
- 2016-10-18 PE PE2018000570A patent/PE20181296A1/es not_active Application Discontinuation
2018
- 2018-03-05 IL IL257872A patent/IL257872A/en unknown
- 2018-04-20 PH PH12018500859A patent/PH12018500859A1/en unknown
- 2018-04-20 DO DO2018000103A patent/DOP2018000103A/es unknown
- 2018-04-20 EC ECIEPI201830976A patent/ECSP18030976A/es unknown

Also Published As

Publication number	Publication date
DOP2018000103A (es)	2018-10-31
PE20181296A1 (es)	2018-08-07
WO2017070068A1 (fr)	2017-04-27
CN108137506A (zh)	2018-06-08
AU2016341115A1 (en)	2018-04-12
MX2018004794A (es)	2018-06-19
PH12018500859A1 (en)	2018-10-29
EA201890525A1 (ru)	2018-09-28
TW201725199A (zh)	2017-07-16
ECSP18030976A (es)	2018-05-31
IL257872A (en)	2018-06-03
AR106332A1 (es)	2018-01-03

Legal Events

Date	Code	Title	Description
2018-04-10	EEER	Examination request	Effective date: 20180320
2019-12-14	FZDE	Discontinued	Effective date: 20191018

Publication	Publication Date	Title
AU2014274435B2 (en)	2016-07-14	3,4-dihydroisoquinolin-2(1H)-yl compounds
CA2999332A1 (fr)	2017-04-27	Forme cristalline de 2- (2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl -3,4-dihydroisoquinolein -2 (1h)-yl)ethanone pour le traitement de la maladie de parkinson
JP7034941B2 (ja)	2022-03-14	Ｌｓｄ１／ｈｄａｃ二重阻害剤としてのシクロプロピル－アミド化合物
US20230322797A1 (en)	2023-10-12	Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
CA3097692C (fr)	2024-02-20	Derives de pyrazo-tetrahydroisoquinoleine en tant que modulateurs positifs du recepteur d1 de la dopamine
WO2021129629A1 (fr)	2021-07-01	Inhibiteur de l'amplificateur de l'homologue zeste 2 et son utilisation
HK1216314B (en)	2018-04-13	3,4-dihydroisoquinolin-2(1h)-yl compounds